Vaxart Awarded Up to $453 Million by BARDA for Groundbreaking Phase 2b Study on COVID-19 Oral Pill Vaccine’
Vaxart, a dynamic player in the innovative field of vaccine development, has recently announced a significant milestone in its quest to mitigate the global impact of COVID-19. The company has been awarded a Project NextGen fund by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $453 million. This substantial financial endorsement aims to support a pivotal Phase 2b clinical study, devised to meticulously evaluate Vaxart’s next-generation oral pill vaccine against an established mRNA vaccine.
This forthcoming study, poised to become a landmark in vaccine research, will encompass a robust cohort of 10,000 participants. Its primary is to analyze the comparative efficacy and safety profile of Vaxart’s oral pill vaccine in juxtaposition with a currently approved mRNA vaccine. Such a large-scale investigation not only underscores the promise demonstrated by Vaxart’s innovative approach but also represents a critical step in the diversification of COVID-19 vaccine platforms, potentially enhancing global vaccine accessibility and compliance due to its non-invasive, user-friendly format.
The scope and ambition of the project are further highlighted by previous announcements that Vaxart has secured an additional $9.27 million from BARDA as part of the Project NextGen initiative. These funds have been earmarked specifically to prepare the groundwork for the Phase 2b clinical study, ensuring that all necessary preclinical activities, regulatory submissions, and logistical frameworks are firmly in place.
The investigational product spotlighted in this study is Vaxart’s next-generation oral pill XBB COVID-19 vaccine. By focusing on an oral administration route, Vaxart aims to revolutionize the vaccine landscape, offering a needle-free alternative that could significantly improve vaccination rates, particularly in populations wary of injectable vaccines.
The success of a 10,000-subject Phase 2b study would be a watershed moment for Vaxart and the broader medical community, laying the groundwork for subsequent Phase 3 trials and potential Emergency Use Authorization (EUA) or full approval by regulatory authorities. This study’s results are eagerly anticipated by healthcare stakeholders, public health officials, and the general public, as they could potentially reshape strategies for combating COVID-19 and other infectious diseases.
In conclusion, Vaxart’s receipt of substantial funding from BARDA for its Phase 2b study is not just a vote of confidence in their oral pill vaccine candidate but also a significant stride towards innovative solutions in the ongoing fight against the COVID-19 pandemic. The upcoming trial’s outcomes have the potential to usher in a new era of vaccine administration, characterized by greater convenience, accessibility, and public acceptance.’Vaxart Secures Up to $453 Million from BARDA for Phase 2b Study of Revolutionary COVID-19 Oral Pill Vaccine’
Comments